ResearchRationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.
ResearchRationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the 'Cardiac Benefits' of Empagliflozin Independent of its Hypoglycemic Activity?
ResearchRationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
ResearchDo ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients?